Stockholders’ Equity (Details Narrative) - USD ($)						3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 12, 2024	Dec. 29, 2023	Jun. 02, 2023	Jan. 19, 2023	Sep. 14, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jul. 12, 2023	Jul. 11, 2023	Jul. 10, 2023	May 12, 2023
Common stock, shares authorized						975,000,000		975,000,000		975,000,000	975,000,000	97,500,000
Accrued bonus compensation						$ 505,000		$ 505,000		$ 710,000
Shares issued						43,220		43,220
Sharebased compensation arrangement by sharebased payment award, options, grants in period, gross								120,000
Liquidation preference								The Series V: (i) is non-convertible, (ii) has a 20% liquidation preference over the shares of common stock, (iii) is non-voting and (iv) has certain rights to dividends and distributions (at the discretion of the Board).
Preferred stock value
Restricted Stock [Member]
Grants approved	50,000
Vest description	vest annually over a 5-year period (10,000 per year) with the first vesting date of December 31, 2024 and each subsequent vesting on the one-year anniversary of the first vesting date, subject to continued employment on each applicable vesting date.	vest annually over a 5-year period (10,000 per year) with the first vesting date of December 31, 2024 and each subsequent vesting on the one-year anniversary of the first vesting date, subject to continued employment on each applicable vesting date.
2021 Equity Incentive Plan [Member]
Number of additional shares authorized												12,000,000	7,000,000
Series V Preferred Stock [Member]
Liquidation preference								The distribution of Series V shares was approved and completed on June 2, 2023 to shareholders as of the record date of May 12, 2023. The Series V: (i) is non-convertible, (ii) has a 20% liquidation preference over the shares of common stock, (iii) is non-voting, and (iv) has certain rights to dividends and distributions (at the discretion of the Board of Directors).
Preferred stock value						$ 2,563,938		$ 2,563,938		$ 2,563,938
Vesting shares issued										25,026
Common Stock [Member]
Share based payment issued						25,781	31,647	410,915	423,089
Sharebased compensation arrangement by sharebased payment award, options, grants in period, gross								370,928
Number of shares issued						163,831	350,018	163,831	651,172
Preferred Stock [Member] | Series V Preferred Stock [Member]
Share based payment issued
Number of shares issued			14,542,803
Preferred stock value														$ 2,560,000
Each Independent Director [Member]
Stock option grant date fair value				$ 50,000
Each Independent Director [Member] | Four Equal Installments [Member]
Stock option grant date fair value				$ 12,500
Independent Directors [Member]
Share based payment issued								39,987
Officer [Member] | Common Stock [Member]
Share based compensation								414,148
Accrued bonus compensation						$ 675,000		$ 675,000
Mr. Allen [Member] | Restricted Stock [Member]
Grants approved		50,000
Mr. Handerhan [Member] | Restricted Stock [Member]
Grants approved		50,000
Mr. Prevoznik [Member] | Restricted Stock [Member]
Grants approved	50,000	50,000
Mr. Paranjape [Member] | Restricted Stock [Member]
Grants approved	50,000	50,000
At-the-Market Offering Agreement [Member]
Sale of stock, number of shares issued in transaction								163,831
Gross proceeds from issuance of common stock								$ 252,000
Shares issued, price per share						$ 1.54		$ 1.54
Proceeds from issuance of stock net								$ 240,000
At-the-Market Offering Agreement [Member] | H.C. Wainwright And Co LLC [Member] | Maximum [Member]
Proceeds from issuance of common stock					$ 98,767,500
At-the-Market Offering Agreement [Member] | H.C. Wainwright and Co., LLC [Member]
Percentage of gross proceeds of offerings					3.00%